Prelude Therapeutics is a privately held, clinical-stage precision oncology company based in Wilmington, DE. Prelude is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/24/20 | $50,000,000 | Series C |
Fidelity Management & Research Company OrbiMed Advisors | undisclosed |
